Biotech Roivant takes aim at resistant infections with $667.5M Intron deal
Fresh from a $200 million fundraising that pushed its valuation above $7 billion, Roivant Sciences has spent more money on its R&D portfolio, licensing a midstage drug for resistant bacteria from South Korea’s Intron Biotechnology.
Vivek Ramaswamy’s fast-growing biotech group is paying $10 million upfront for rights to SAL200 (Tonabacase), a biologic it says is based on an enzyme (endolysin) derived from a bacteriophage—a virus that infects bacteria—that acts by breaking down bacterial cell walls.
The mechanism is unlike that of any current antibiotic class and, according to Intron, could develop into a new approach to the big problem of antimicrobial resistance in bacterial pathogens, including superbugs like MRSA and other staphylococcal infections, because it doesn’t involve the use of inhibitors that can induce the development of resistance mutations.
Following its usual pattern, the Swiss umbrella group plans to set up a new subsidiary to handle development and commercialization of the endolysin candidates, although it hasn’t yet revealed a name for the unit. It already has 12 companies grouped around therapeutic categories and a healthcare data unit, but until now its only presence in anti-infectives has been in hepatitis B with Arbutus and Sinovant’s lefamulin for community-acquired bacterial pneumonia.
“The development of novel anti-infective therapies is one of the greatest needs of our time,” said Roivant President Mayukh Sukhatme, M.D., during a signing ceremony for the deal with Intron’s CEO Kyung Won Yoon. “We hope to maximize the impact of SAL200 on public health through innovative approaches to both development and commercialization.”
Source: FierceBiotechSmart Innovations